Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Last €65.61 EUR
Change Today +1.35 / 2.11%
Volume 614.0
As of 5:31 AM 02/10/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Lilly Corporate Center

Indianapolis, IN 46285

United States

Phone: 317-276-2000


NSCLC. Cardiovascular Products The company’s cardiovascular products include Cialis, for the treatment of erectile dysfunction and benign prostatic hyperplasia; Effient, for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are managed with an artery-opening procedure known as percutaneous coronary intervention (PCI), including patients undergoing angioplasty, atherectomy, or stent placement; and ReoPro, for use as an adjunct to PCI for the prevention of cardiac ischemic complications. Animal Health Products segment This segment’s products for food animals include Rumensin, a cattle feed additive that improves feed efficiency and growth and also controls and prevents coccidiosis; Posilac, a protein supplement to improve milk productivity in dairy cows; Paylean and Optaflexx, leanness and performance enhancers for swine and cattle, respectively; Tylan, an antibiotic used to control certain diseases in cattle, swine, and poultry; Micotil, Pulmotil, and Pulmotil AC, antibiotics used to treat respiratory disease in cattle, swine, and poultry, respectively; Coban, Monteban, and Maxiban, anticoccidial agents for use in poultry; and Surmax (sold as Maxus in some countries), a performance improver for swine and poultry. The company’s products for companion animals include Trifexis, a monthly chewable tablet for dogs that kills fleas, prevents flea infestations, prevents heartworm disease, and controls intestinal parasite infections; and Comfortis, a chewable tablet that kills fleas and prevents flea infestations on dogs. In January 2015, the company completed its acquisition of Novartis Animal Health (Novartis AH). Newly acquired Novartis AH products include Denagard, an antibiotic for the control and treatment of respiratory and enteric diseases in swine and poultry; Milbemax, a spectrum intestinal wormer which, if given monthly, also offers prevention against heartworm; Sentinel (outside the U.S.), a monthly tablet for the prevention of flea populations, the concurrent prevention of heartworm disease and the treatment of roundworms, hookworms, and whipworms in dogs; Atopica, for the treatment of chronic manifestations of atopic dermatitis in dogs and for the symptomatic treatment of chronic allergic dermatitis in cats; and Fortekor, for the treatment of congestive heart failure in dogs and reduction of proteinurea associated with chronic kidney disease in cats. Marketing The company sells majority of its products worldwide. Human Pharmaceuticals—U.S.: In the U.S., the company distributes human pharmaceutical products principally through independent wholesale distributors, with some sales directly to pharmacies. In 2014, three wholesale distributors in the U.S.—AmerisourceBergen Corporation, McKesson Corporation, and Cardinal Health, Inc.—each accounted for between 8 percent and 19 percent of the company’s consolidated total revenue. The company promotes its major human pharmaceutical products in the U.S. through sales representatives who call upon physicians and other health care professionals. The company maintains special business groups to service wholesalers, pharmacy benefit managers, managed care organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. Human Pharmaceuticals—Outside the U.S.: Outside the U.S, the company promotes its human pharmaceutical products primarily through sales representatives. In various countries in which the company operates, it maintains its own sales organizations, but in some smaller countries that the company markets its products through independent distributors. Human Pharmaceutical Marketing Collaborations Certain of the company’s human pharmaceutical products are marketed in arrangements with other pharmaceutical companies, including the following: Trajenta, Jentadueto, Jardiance, and Glyxambi are being jointly developed and commercialized with the company by Boehringer Ingelheim GmbH. The company’s collaboration with Boehringer Ingelheim GmbH also covers two future diabetes products, such as its new insulin glargine product and


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:GR €65.61 EUR +1.35

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $53.48 USD +0.59
Allergan plc $272.34 USD +6.04
AstraZeneca PLC 3,965 GBp +50.00
Novo Nordisk A/S kr323.40 DKK +17.00
Teva Pharmaceutical Industries Ltd $57.67 USD +0.74
View Industry Companies

Industry Analysis


Industry Average

Valuation LLY Industry Range
Price/Earnings 32.8x
Price/Sales 4.0x
Price/Book 5.2x
Price/Cash Flow 34.1x
TEV/Sales 3.5x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ELI LILLY & CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at